September 26, 2021
  • September 26, 2021

Eye diseases

Bio-imprinted insulin-releasing biocomposites hold promise for the treatment of diabetes ”3D Printing Media Network

by on September 16, 2021 0

Stay up to date with everything that is happening in the wonderful world of AM through our LinkedIn community. Fluicell, a Swedish bioprinting startup founded in 2012 as a spin-out of Chalmers University of Technology, has undertaken research to develop drugs for the treatment of type 1 diabetes. The project, which recently reached a...

Read More

Ophthalmologists at Moorfields Eye Hospital in Abu Dhabi restore vision to patient with Down syndrome

by on September 4, 2021 0

Abu Dhabi, United Arab Emirates: Ophthalmologists at Moorfields Eye Hospital Abu Dhabi, part of United Eastern Medical Services (UEMedical) and a Mubadala Health Partner, have successfully restored the vision of a 40-year-old UAE patient with Down syndrome. The patient had one of her eyes removed at a younger age due to complications from glaucoma...

Read More

The Italian guarantee loan for SIFI

by on September 1, 2021 0

Carbonetti e Associati advised SIFI, an Italian ophthalmic pharmaceutical company that provides solutions for the treatment of eye diseases, on a loan granted by a pool of five banks (assisted by Simmons & Simmons) and backed by the Italian Guarantee issued by SACE. The aim of the measure was to support the company in...

Read More

How artificial intelligence helps prevent blindness

by on August 25, 2021 0

Artificial intelligence (AI) often refers to computer systems that can perform a task through specific programming or by learning from data. Artificial intelligence has been used for decades in various fields such as computer science, engineering and biomedical research. One of the most common applications of artificial intelligence is image recognition and computer vision....

Read More

Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent® Technologies

by on August 23, 2021 0

SAN CLEMENTE, Calif .– (COMMERCIAL THREAD) – Glaukos Corporation (NYSE: GKOS), an ophthalmic and pharmaceutical medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced a milestone without precedent of clinical data from 200 peer-reviewed publications highlighting the efficacy and safety of iStent® technologies around...

Read More